{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:10:13Z","timestamp":1756458613660,"version":"3.44.0"},"reference-count":49,"publisher":"Becaris Publishing Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            This systematic review aimed to evaluate the comparative efficacy, safety and cost-effectiveness of safinamide (50\/100\u00a0mg) versus rasagiline (1\u00a0mg) in managing Parkinson\u2019s disease (PD).\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Randomized clinical trials were identified through systematic searches of PubMed, Embase and Cochrane databases (last searched September 2023). Eligibility criteria included studies assessing Unified Parkinson\u2019s Disease Rating Scale (UPDRS) scores, On\/Off time and adverse events. Risk of bias was evaluated using funnel plots, and data synthesis employed odds ratios, number needed to treat (NNT) and incremental cost-effectiveness ratios, calculated using the current costs of safinamide and rasagiline in Spain.\n            <jats:bold>Results:<\/jats:bold>\n            Thirteen trials (n\u00a0=\u00a04157 participants) were included. Safinamide demonstrated greater efficacy (NNT-UPDRS: 6 vs 8) and safety (number needed to harm-serious adverse events: 135 vs 83) compared with rasagiline. The benefit-risk balance of safinamide was superior, as evidenced by higher likelihood of being helped over harmed ratios. Cost-effectiveness analysis revealed lower costs per NNT for On\/Off time with safinamide. While rasagiline treated more patients within a fixed budget, safinamide achieved better responder-to-nonresponder ratios.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Safinamide showed superior efficacy, safety and cost-efficiency compared with rasagiline, supporting its use as a preferred adjunct therapy for PD. Limitations include reliance on clinical trial data and Spanish cost models. Future research incorporating real-world evidence is warranted.\n          <\/jats:p>","DOI":"10.57264\/cer-2025-0031","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T10:08:01Z","timestamp":1755166081000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-6993","authenticated-orcid":false,"given":"Antonio J","family":"Garc\u00eda Ruiz","sequence":"first","affiliation":[{"name":"Department of Pharmacology &amp; Pediatrics, School of Medicine, University of Malaga, Biomedical Research Institute of Malaga (IBIMA-Bionand), Malaga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester Morales","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Virgen de la Victoria, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"G\u00f3mez Heredia","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Virgen de la Victoria, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco P\u00e9rez","family":"Errazquin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Virgen de la Victoria, M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2979-5241","authenticated-orcid":false,"given":"Nuria Garc\u00eda-Agua","family":"Soler","sequence":"additional","affiliation":[{"name":"Department of Pharmacology &amp; Pediatrics, School of Medicine, University of Malaga, Biomedical Research Institute of Malaga (IBIMA-Bionand), Malaga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"8","key":"e_1_3_6_2_2","first-page":"504","article-title":"Parkinson's disease and its management: Part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis","volume":"40","author":"DeMaagd G","year":"2015","unstructured":"DeMaagd G, Philip A. Parkinson's disease and its management: Part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. P.T. 40(8), 504\u2013532 (2015).","journal-title":"P.T."},{"issue":"7","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/mds.27037","article-title":"Aging and Parkinson's disease: different sides of the same coin?","volume":"32","author":"Collier TJ","year":"2017","unstructured":"Collier TJ, Kanaan NM, Kordower JH. Aging and Parkinson's disease: different sides of the same coin? Mov. Disord. 32(7), 983\u2013990 (2017).","journal-title":"Mov. Disord."},{"key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fneur.2019.00218","article-title":"Parkinson's disease and the environment","volume":"10","author":"Ball N","year":"2019","unstructured":"Ball N, Teo WP, Chandra S, Chapman J. Parkinson's disease and the environment. Front. Neurol. 10, 218 (2019).","journal-title":"Front. Neurol."},{"key":"e_1_3_6_5_2","unstructured":"World Health Organization. Parkinson disease: a public health approach: technical brief (2022)."},{"issue":"3","key":"e_1_3_6_6_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mds.25292","article-title":"The current and projected economic burden of Parkinson's disease in the United States","volume":"28","author":"Kowal SL","year":"2013","unstructured":"Kowal SL, Dall TM, Chakrabarti R, Storm MV, Jain A. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord. 28(3), 311\u2013318 (2013).","journal-title":"Mov. Disord."},{"key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","article-title":"Global trends in the incidence, prevalence, and years lived with disability of Parkinson's Disease in 204 countries\/territories from 1990 to 2019","volume":"9","author":"Ou Z","year":"2021","unstructured":"Ou Z, Pan J, Tang S Global trends in the incidence, prevalence, and years lived with disability of Parkinson's Disease in 204 countries\/territories from 1990 to 2019. Front. Public Health 9, 776847 (2021).","journal-title":"Front. Public Health"},{"key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3233\/JPD-181474","article-title":"The emerging evidence of the Parkinson pandemic","volume":"8","author":"Dorsey ER","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J. Parkinsons Dis. 8, S3\u2013S8 (2018).","journal-title":"J. Parkinsons Dis."},{"key":"e_1_3_6_9_2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134427","article-title":"Levodopa-induced dyskinesias in Parkinson's disease: an overview on pathophysiology, clinical manifestations, therapy management strategies and future directions","volume":"12","author":"di Biase L","year":"2023","unstructured":"di Biase L, Pecoraro PM, Carbone SP, Caminiti ML, Di Lazzaro V. Levodopa-induced dyskinesias in Parkinson's disease: an overview on pathophysiology, clinical manifestations, therapy management strategies and future directions. J. Clin. Med. 12, (2023).","journal-title":"J. Clin. Med."},{"key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3233\/JPD-212976","article-title":"Monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: past, present, and future","volume":"12","author":"Tan YY","year":"2022","unstructured":"Tan YY, Jenner P, Chen SD. Monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: past, present, and future. J. Parkinsons Dis. 12, 477\u2013493 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"e_1_3_6_11_2","unstructured":"EMA. Rasagiline ratiopharm: EPAR summary for the public. EMA\/723435\/2014. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/rasagiline-ratiopharm-epar-summary-public_en.pdf"},{"key":"e_1_3_6_12_2","unstructured":"EMA. Xadago: EPAR \u2013 Summary for the public. EMA\/181382\/2015. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/xadago-epar-summary-public_en.pdf"},{"key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3961\/jpmph.22.195","article-title":"The primary process and key concepts of economic evaluation in healthcare","volume":"55","author":"Kim Y","year":"2022","unstructured":"Kim Y, Kim Y, Lee HJ The primary process and key concepts of economic evaluation in healthcare. J. Prev. Med. Public Health 55, 415\u2013423 (2022).","journal-title":"J. Prev. Med. Public Health"},{"key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e1000097 (2009).","journal-title":"PLoS Med."},{"key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"e3580","DOI":"10.1371\/journal.pone.0003580","article-title":"Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance","volume":"3","author":"Boada JN","year":"2008","unstructured":"Boada JN, Boada C, Garc\u00eda-S\u00e1iz M, Garc\u00eda M, Fern\u00e1ndez E, G\u00f3mez E. Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance. PLoS ONE 3, e3580 (2008).","journal-title":"PLoS ONE"},{"key":"e_1_3_6_16_2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-017-0875-8","article-title":"Number needed to treat (NNT) in clinical literature: an appraisal","volume":"15","author":"Mendes D","year":"2017","unstructured":"Mendes D, Alves C, Batel-Marques F. Number needed to treat (NNT) in clinical literature: an appraisal. BMC Med. 15, 112 (2017).","journal-title":"BMC Med."},{"key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/jrsm.1260","article-title":"Introduction, comparison, and validation of Meta-Essentials: a free and simple tool for meta-analysis","volume":"8","author":"Suurmond R","year":"2017","unstructured":"Suurmond R, van Rhee H, Hak T. Introduction, comparison, and validation of Meta-Essentials: a free and simple tool for meta-analysis. Res. Synth. Methods 8, 537\u2013553 (2017).","journal-title":"Res. Synth. Methods"},{"key":"e_1_3_6_18_2","unstructured":"Sociedad Espa\u00f1ola de Farmacia Hospitaliria (SEFH). Calculadoras y herramientas sobre subgrupos. Available at: https:\/\/gruposdetrabajo.sefh.es\/genesis\/index.php?option=com_content&view=article&id=45&Itemid=41"},{"key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","article-title":"Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa","volume":"23","author":"Rabey JM","year":"2000","unstructured":"Rabey JM, Sagi I, Huberman M Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin. Neuropharmacol. 23, 324\u2013330 (2000).","journal-title":"Clin. Neuropharmacol."},{"key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study","volume":"62","author":"Parkinson Study Group","year":"2005","unstructured":"Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62, 241\u2013248 (2005).","journal-title":"Arch. Neurol."},{"key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol O","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365, 947\u2013954 (2005).","journal-title":"Lancet"},{"key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1017\/S1461145713000175","article-title":"Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial","volume":"16","author":"Zhang L","year":"2013","unstructured":"Zhang L, Zhang Z, Chen Y Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial. Int. J. Neuropsychopharmacol. 16, 1529\u20131537 (2013).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/mds.23738","article-title":"The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study","volume":"26","author":"Hanagasi HA","year":"2011","unstructured":"Hanagasi HA, Gurvit H, Unsalan P The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov. Disord. 26, 1851\u20131858 (2011).","journal-title":"Mov. Disord."},{"key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1176\/appi.neuropsych.15050118","article-title":"Cognitive effects of rasagiline in mild-to-moderate stage Parkinson's disease without dementia","volume":"29","author":"Frakey LL","year":"2017","unstructured":"Frakey LL, Friedman JH. Cognitive effects of rasagiline in mild-to-moderate stage Parkinson's disease without dementia. J. Neuropsychiatry Clin. Neurosci. 29, 22\u201325 (2017).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/mds.26429","article-title":"Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease","volume":"30","author":"Lim TT","year":"2015","unstructured":"Lim TT, Kluger BM, Rodriguez RL Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease. Mov. Disord. 30, 1825\u20131830 (2015).","journal-title":"Mov. Disord."},{"key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mds.25877","article-title":"Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease","volume":"29","author":"Hauser RA","year":"2014","unstructured":"Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S. ANDANTE study investigators. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. Mov. Disord. 29, 1028\u20131034 (2014).","journal-title":"Mov. Disord."},{"key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.25751","article-title":"Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations","volume":"29","author":"Borgohain R","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov. Disord. 29, 229\u2013237 (2014).","journal-title":"Mov. Disord."},{"key":"e_1_3_6_28_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4467","article-title":"Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial","volume":"74","author":"Schapira AH","year":"2017","unstructured":"Schapira AH, Fox SH, Hauser RA Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 74, 216\u2013224 (2017).","journal-title":"JAMA Neurol."},{"key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.parkreldis.2020.04.012","article-title":"Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: a randomized, double-blind, placebo-controlled, Phase II\/III study","volume":"75","author":"Hattori N","year":"2020","unstructured":"Hattori N, Tsuboi Y, Yamamoto A, Sasagawa Y, Nomoto M. ME2125-3 Study Group. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: a randomized, double-blind, placebo-controlled, Phase II\/III study. Parkinsonism Relat. Disord. 75, 17\u201323 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"e_1_3_6_30_2","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ene.12724","article-title":"A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients","volume":"22","author":"Barone P","year":"2015","unstructured":"Barone P, Santangelo G, Morgante L A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. Eur. J. Neurol. 22, 1184\u20131191 (2015).","journal-title":"Eur. J. Neurol."},{"key":"e_1_3_6_31_2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s40263-022-00958-6","article-title":"The XINDI Study: A randomized Phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese patients with Parkinson's disease with motor fluctuations","volume":"36","author":"Wei Q","year":"2022","unstructured":"Wei Q, Tan Y, Xu P The XINDI Study: A randomized Phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese patients with Parkinson's disease with motor fluctuations. CNS Drugs 36, 1217\u20131227 (2022).","journal-title":"CNS Drugs"},{"key":"e_1_3_6_32_2","first-page":"495","article-title":"Understanding the effect of economic recession on healthcare services: a systematic review","volume":"51","author":"Recio RS","year":"2022","unstructured":"Recio RS, Pablo Alonso P\u00e9rez De \u00c1greda J, Jos\u00e9 Rabanaque M, Aguilar Palacio I. Understanding the effect of economic recession on healthcare services: a systematic review. Iran J. Public Health 51, 495\u2013507 (2022).","journal-title":"Iran J. Public Health"},{"key":"e_1_3_6_33_2","doi-asserted-by":"crossref","first-page":"103097","DOI":"10.1016\/j.futures.2023.103097","article-title":"Medicine of the future: how and who is going to treat us?","volume":"146","author":"Kulkova J","year":"2023","unstructured":"Kulkova J, Kulkov I, Rohrbeck R Medicine of the future: how and who is going to treat us? Futures 146, 103097 (2023).","journal-title":"Futures"},{"key":"e_1_3_6_34_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40801-023-00410-1","article-title":"Economic burden of Parkinson's disease: a multinational, real-world, cost-of-illness study","volume":"11","author":"Chaudhuri KR","year":"2024","unstructured":"Chaudhuri KR, Azulay JP, Odin P Economic burden of Parkinson's disease: a multinational, real-world, cost-of-illness study. Drugs Real World Outcomes 11, 1\u201311 (2024).","journal-title":"Drugs Real World Outcomes"},{"key":"e_1_3_6_35_2","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis A","year":"1988","unstructured":"Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N. Engl. J. Med. 318, 1728\u20131733 (1988).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_36_2","unstructured":"Eslava AO Gil RM Fuentes MDF L\u00f3pez-Briz E Latorre FP. Gu\u00eda de evaluaci\u00f3n econ\u00f3mica e impacto presupuestario en los informes de evaluaci\u00f3n de medicamentos. (2017)."},{"key":"e_1_3_6_37_2","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.4088\/JCP.15f09870","article-title":"The numbers needed to treat and harm (NNT, NNH) statistics: what they tell us and what they do not","volume":"76","author":"Andrade C","year":"2015","unstructured":"Andrade C. The numbers needed to treat and harm (NNT, NNH) statistics: what they tell us and what they do not. J. Clin. Psychiatry 76, e330\u2013333 (2015).","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_3_6_38_2","first-page":"210","article-title":"Individualizing treatment decisions \u2013 the likelihood of being helped or harmed","volume":"25","author":"Straus SE","year":"2002","unstructured":"Straus SE. Individualizing treatment decisions \u2013 the likelihood of being helped or harmed. Eval. Health Prof. 25, 210\u2013224 (2002).","journal-title":"Eval. Health Prof."},{"key":"e_1_3_6_39_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.phrs.2003.12.004","article-title":"Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity","volume":"50","author":"Marzo A","year":"2004","unstructured":"Marzo A, Dal Bo L, Monti NC Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol. Res. 50, 77\u201385 (2004).","journal-title":"Pharmacol. Res."},{"key":"e_1_3_6_40_2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/1570159X16666180830100754","article-title":"Different generations of type-B monoamine oxidase inhibitors in Parkinson's disease: from bench to bedside","volume":"17","author":"Alborghetti M","year":"2019","unstructured":"Alborghetti M, Nicoletti F. Different generations of type-B monoamine oxidase inhibitors in Parkinson's disease: from bench to bedside. Curr. Neuropharmacol. 17, 861\u2013873 (2019).","journal-title":"Curr. Neuropharmacol."},{"key":"e_1_3_6_41_2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/j.1476-5381.2009.00550.x","article-title":"Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development","volume":"159","author":"Bodrogi J","year":"2010","unstructured":"Bodrogi J, Kal\u00f3 Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br. J. Pharmacol. 159, 1367\u20131373 (2010).","journal-title":"Br. J. Pharmacol."},{"key":"e_1_3_6_42_2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/10543406.2013.860157","article-title":"Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis","volume":"24","author":"Bang H","year":"2014","unstructured":"Bang H, Zhao H. Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis. J. Biopharm. Stat. 24, 443\u2013460 (2014).","journal-title":"J. Biopharm. Stat."},{"key":"e_1_3_6_43_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fphar.2010.00115","article-title":"How to assess the value of medicines?","volume":"1","author":"Simoens S","year":"2010","unstructured":"Simoens S. How to assess the value of medicines? Front. Pharmacol. 1, 115 (2010).","journal-title":"Front. Pharmacol."},{"key":"e_1_3_6_44_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12910-024-01036-w","article-title":"A QALY is [still] a QALY is [still] a QALY?","volume":"25","author":"Mahdiani H","year":"2024","unstructured":"Mahdiani H, M\u00fcnch N, Paul NW. A QALY is [still] a QALY is [still] a QALY? BMC Medical Ethics 25, 35 (2024).","journal-title":"BMC Medical Ethics"},{"key":"e_1_3_6_45_2","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hec.3633","article-title":"Estimating a cost-effectiveness threshold for the Spanish NHS","volume":"27","author":"Vallejo-Torres L","year":"2018","unstructured":"Vallejo-Torres L, Garc\u00eda-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 27, 746\u2013761 (2018).","journal-title":"Health Econ."},{"issue":"2","key":"e_1_3_6_46_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.gaceta.2019.06.007","article-title":"\u00bfQu\u00e9 es una intervenci\u00f3n sanitaria eficiente en Espa\u00f1a en 2020? [What is an efficient health intervention in Spain in 2020?]","volume":"34","author":"Sacrist\u00e1n JA","year":"2020","unstructured":"Sacrist\u00e1n JA, Oliva J, Campillo-Artero C \u00bfQu\u00e9 es una intervenci\u00f3n sanitaria eficiente en Espa\u00f1a en 2020? [What is an efficient health intervention in Spain in 2020?]. Gac. Sanit. 34(2), 189\u2013193 (2020).","journal-title":"Gac. Sanit."},{"key":"e_1_3_6_47_2","doi-asserted-by":"crossref","first-page":"A35","DOI":"10.1016\/j.jval.2015.03.207","article-title":"The expanded number needed to treat: applying the concept of NNT to continuous health economic outcomes","volume":"18","author":"O'Day K","year":"2015","unstructured":"O'Day K, Campbell D. The expanded number needed to treat: applying the concept of NNT to continuous health economic outcomes. Value Health 18, A35 (2015).","journal-title":"Value Health"},{"key":"e_1_3_6_48_2","first-page":"100039","article-title":"Availability and use of number needed to treat (NNT) based decision aids for pharmaceutical interventions","volume":"2","author":"Nguyen C","year":"2021","unstructured":"Nguyen C, Naunton M, Thomas J Availability and use of number needed to treat (NNT) based decision aids for pharmaceutical interventions. Explor. Res. Clin. Soc. Pharm. 2, 100039 (2021).","journal-title":"Explor. Res. Clin. Soc. Pharm."},{"key":"e_1_3_6_49_2","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.37765\/ajmc.2020.88518","article-title":"The economic impact of OFF periods in Parkinson disease","volume":"26","author":"Abeynayake I","year":"2020","unstructured":"Abeynayake I, Tanner CM. The economic impact of OFF periods in Parkinson disease. Am. J. Manag. Care 26, S265\u2013S269 (2020).","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_6_50_2","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/j.1468-1331.2010.02984.x","article-title":"Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany","volume":"17","author":"Winter Y","year":"2010","unstructured":"Winter Y, Balzer-Geldsetzer M, Spottke A Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany. Eur. J. Neurol. 17, 1156\u20131163 (2010).","journal-title":"Eur. J. Neurol."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:53:47Z","timestamp":1756457627000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.57264\/cer-2025-0031"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0031","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"e250031"}}